Posts

Otsuka’s VOYXACT Shows First IgAN Therapy to Stabilize Kidney Function Decline to Normal Physiologic Levels

on

Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program

on

FDA Approves Otsuka's Tool SIMTRIYO

on

Vera’s IgAN Approval Kicks Off Competition with Otsuka

on

Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears – 2026 analysis

on

Otsuka touts new IgAN evidence as it seeks full approval for Voyxact

on

Otsuka's $1.225B Acquisition of Transcend Therapeutics for PTSD Neuroplastogen TSND-201

on

Otsuka's Anti-APRIL Antibody (Voyxact/Sibeprenlimab) Receives FDA Approval for IgA Nephropathy (IgAN)

on

Otsuka Acquires Asia-Pacific Rights to 4D Molecular Therapeutics' Retinal Gene Therapy 4D-150 for $85 Million

on

FDA Rejects Lundbeck and Otsuka's Rexulti for PTSD on Insufficient Efficacy Evidence

on

FDA Advisory Committee Rejects Lundbeck and Otsuka's PTSD Bid for Rexulti

on

Otsuka's Phase 3 IgAN Win with Sibeprenlimab Shakes Vera's Stock

on